Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001792" target="_blank" >RIV/65269705:_____/12:#0001792 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/13:00067535 RIV/65269705:_____/13:#0002041

Result on the web

<a href="http://dx.doi.org/10.1002/hon.2018" target="_blank" >http://dx.doi.org/10.1002/hon.2018</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/hon.2018" target="_blank" >10.1002/hon.2018</a>

Result language

angličtina

Original language name

Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients

Original language description

We investigated the prognostic value of amp(1q21) alone and in combination with other abnormalities in newly diagnosed myeloma patients. The study group consisted of 104 patients treated with various induction regimens, mostly thalidomide based (87 patients). Amp(1q21) was detected in 49 (47.1%) of patients; in 26 (25.0%) cases, it was combined with del(13q14), in 7 (6.7%) with del(17p13) and in 15 (14.4%) with t(4;14)( p16;q32). The response rate was significantly better in amp(1q21)-negative than in amp(1q21)-positive patients (74.5% vs 55.1%, p = 0.025; complete response 18.2% vs 4.1%, p = 0.024). The median progression-free survival (PFS) was 33.9months in patients without amp(1q21) and 10.3months with this aberration ( p = 0.002). The presence ofadditional abnormalities resulted in significantly shortened PFS when compared with patients with isolated amp (1q21): coexisting del(13q14) resulted in 7.8 vs 29.0months of PFS ( p = 0.024) and del (17p13) resulted in 4.0 vs 24.9months o

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Hematological Oncology

ISSN

0278-0232

e-ISSN

—

Volume of the periodical

30

Issue of the periodical within the volume

1

Country of publishing house

US - UNITED STATES

Number of pages

9

Pages from-to

1-8

UT code for WoS article

000315968100008

EID of the result in the Scopus database

—